GlassScriptPhysician profile
Anne C Maynard
NPI 1336476985
$8,747.38
in general payments reported to CMS, 2019-2025
35 companies · $1,992 in 2025
The $1,992 reported for 2025 was more than what 96% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,480 · 2022: $1,588 · 2023: $1,794 · 2024: $1,894 · 2025: $1,992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,550 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,550.13 |
| Education | $129.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,366.04 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $1,270.99 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $1,200.92 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $812.25 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Amgen INC. | $547.89 | 2021-2025 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $541.09 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $476.37 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $416.39 | 2021-2024 | Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $338.74 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.55 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Insulet Corporation | $227.09 | 2022-2025 | Omnipod |
| Medtronic, INC. | $150.17 | 2021-2025 | Minimed 780g |
| Sk Life Science, INC. | $96.69 | 2024 | Xcopri |
| Radius Health, INC. | $92.26 | 2025 | Tymlos |
| Sequel Med Tech, LLC | $88.50 | 2025 | Twiist |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amphastar Pharmaceuticals, INC. | $76.30 | 2024-2025 | |
| Beta Bionics, INC. | $76.26 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Antares Pharma, INC. | $72.72 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Amneal Pharmaceuticals LLC | $69.73 | 2024-2025 | Unithroid |
| Abbvie INC. | $61.57 | 2021-2025 | |
| Ascendis Pharma Endocrinology INC | $48.98 | 2025 | Yorvipath |
| Roche Diabetes Care, INC. | $39.22 | 2021 | |
| Mannkind Corporation | $38.79 | 2021-2025 | |
| Verity Pharmaceuticals INC. | $36.01 | 2025 | Tlando |
| Ibsa Pharma INC. | $32.54 | 2025 | Tirosint, Licart, Flector |
| Neurocrine Biosciences, INC. | $31.53 | 2023 | |
| Theracosbio, LLC | $31.17 | 2024 | Brenzavvy |
| Almatica Pharma LLC | $30.86 | 2025 | Teriparatide |
| Ascensia Diabetes Care US INC. | $29.12 | 2022 | |
| Chiesi USA, INC. | $28.63 | 2025 | Mycapssa |
| Corcept Therapeutics | $23.79 | 2025 | Korlym |
| Sun Pharmaceutical Industries INC. | $21.02 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $18.73 | 2025 | Imcivree |
| Glaxosmithkline, LLC. | $17.68 | 2024 | Arexvy, Shingrix |
| Embecta Corp. | $15.79 | 2023 | Bd Nano 2nd Gen Pen Needle |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Maynard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.